Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11030142 | 1.00 | GSK3A (0.41) | GSK3AGSK3BMPIKAT2BLMNA | |
| SCHEMBL9008472 | 0.68 | GSK3A (0.40) | GSK3AGSK3BMPIKAT2BLMNA | |
| SCHEMBL9576566 | 0.68 | GSK3A (0.37) | GSK3AGSK3BMPILMNAKMT2A | |
| SCHEMBL10547158 | 0.67 | GSK3A (0.42) | GSK3AGSK3BMPILMNAPOLB | |
| SCHEMBL8621565 | 0.65 | MPI (0.57) | MPIGAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29239065 | 0.63 | GSK3A (0.65) | GSK3AGSK3BMPILMNAPOLB | |
| SCHEMBL21033019 | 0.62 | MPI (0.58) | MPINPSR1ALDH1A1MAPTKDM4E | |
| SCHEMBL9130580 | 0.60 | GSK3A (0.37) | GSK3AGSK3BMPIKMT2AALDH1A1 | |
| SCHEMBL11320066 | 0.60 | DUSP3 (0.61) | LMNAPOLBGAAKMT2AMEN1 | |
| SCHEMBL11330732 | 0.60 | DUSP3 (0.61) | LMNAPOLBGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260081163-A1 | NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | Panasonic Energy Co., Ltd. (JP) | 2026-03-19 | — | — | US | claimed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250041352-A1 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | SPINALCYTE LLC (US) | 2025-02-06 | — | — | US | claimed |
| WO-2024048117-A1 | NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | パナソニックエナジー株式会社 | 2024-03-07 | — | — | WO | claimed |
| US-20240024365-A1 | POTENTIATION OF BONE MARROW CELL ACTIVITY BY COADMINISTRATION WITH OXYTOCIN | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-01-25 | — | — | US | claimed |
| WO-2023233771-A1 | METHOD FOR SUPPRESSING DECOMPOSITION OF ISOTHIAZOLINE COMPOUND IN AQUEOUS SYSTEM | 栗田工業株式会社 | 2023-12-07 | — | — | WO | claimed |
| US-20220395538-A1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC | 2022-12-15 | — | — | US | claimed |
| EP-4058037-A1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | Figene, LLC (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2022144120-A1 | COMMUNICATION SYSTEM INCLUDING DEVICES WITH SDR CHIP | Nagravision Sàrl (CH) | 2022-07-07 | — | — | WO | claimed |
| EP-3941585-A1 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | Figene, LLC (US) | 2022-01-26 | — | — | EP | claimed |
| EP-0258999-A1 | Process for preparing isothiazolones | ROHM AND HAAS COMPANY (US) | 1988-03-09 | — | — | EP | claimed |
| US-4685932-A | PROCESSING THROUGH LIQUID MEDIA CONTAINING SAME CONCENTRATION OF MICROBIOCIDE | MORTON THIOKOL, INC. (US) | 1987-08-11 | — | — | US | claimed |
| US-4686239-A | WITHIN PORES OF THERMOPLASTIC POWDER; | MORTON THIOKOL, INC. (US) | 1987-08-11 | — | — | US | claimed |
| US-4663359-A | POROUS THERMOPLASTIC, NON-DUSTING | MORTON THIOKOL, INC. (US) | 1987-05-05 | — | — | US | claimed |
| US-4661528-A | HIGH CONCENTRATION, POROUS THERMOPLASTIC POWDER, NON-DUSTING AND FREE-FLOWING | MORTON THIOKOL, INC. (US) | 1987-04-28 | — | — | US | claimed |
| US-4649079-A | Method of incorporating antimicrobial agents into fibers | MORTON THIOKOL INC. (US) | 1987-03-10 | — | — | US | claimed |
| US-4542169-A | Biomedical devices containing isothiazolones to control bacteria growth | ROHM AND HAAS COMPANY (US) | 1985-09-17 | — | — | US | claimed |
| EP-0147970-A1 | Microbiocidal or antimicrobial biomedical devices | ROHM AND HAAS COMPANY (US) | 1985-07-10 | — | — | EP | claimed |
| US-4173643-A | 4-ISOTHIAZOLINE-3-ONES | ROHM AND HAAS COMPANY (US) | 1979-11-06 | — | — | US | claimed |
| US-4127687-A | PAINTING WITH ISOTHIAZOLONES | ROHM AND HAAS COMPANY (US) | 1978-11-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260081163-A1 | NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | SLC9B2, SLC9A1, SLC9A2 | GSK3A 2864/4885GSK3B 2354/4885MPI 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.